New Search

Export article

Trial of Deferiprone in Parkinson’s Disease

David Devos, Julien Labreuche, Olivier Rascol, Jean-Christophe Corvol, Alain Duhamel, Pauline Guyon Delannoy, Werner Poewe, Yaroslau Compta, Nicola Pavese, Evžen Růžička,
Show More
Abstract: Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
Keywords: Parkinson / deferiprone / nigra / chelator / pathophysiology / nigrostriatal / substantia / Disease Iron / iron content

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "The New England Journal of Medicine" .
References (23)
    Cited by 1 articles
      Back to Top Top